These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 20204774)

  • 1. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, improves hepatic microcirculatory patency and oxygen availability in a high-fat-diet-induced fatty liver in mice.
    Kondo K; Sugioka T; Tsukada K; Aizawa M; Takizawa M; Shimizu K; Morimoto M; Suematsu M; Goda N
    Adv Exp Med Biol; 2010; 662():77-82. PubMed ID: 20204774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver.
    Harano Y; Yasui K; Toyama T; Nakajima T; Mitsuyoshi H; Mimani M; Hirasawa T; Itoh Y; Okanoue T
    Liver Int; 2006 Jun; 26(5):613-20. PubMed ID: 16762007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
    Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
    Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease.
    Hong XZ; Li LD; Wu LM
    Clin Exp Pharmacol Physiol; 2007; 34(1-2):27-35. PubMed ID: 17201732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice.
    Lalloyer F; Wouters K; Baron M; Caron S; Vallez E; Vanhoutte J; Baugé E; Shiri-Sverdlov R; Hofker M; Staels B; Tailleux A
    Arterioscler Thromb Vasc Biol; 2011 Jul; 31(7):1573-9. PubMed ID: 21474829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fenofibrate, a PPARα agonist, reduces hepatic fat accumulation through the upregulation of TFEB-mediated lipophagy.
    Yoo J; Jeong IK; Ahn KJ; Chung HY; Hwang YC
    Metabolism; 2021 Jul; 120():154798. PubMed ID: 33984335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peroxisomal Fitness: A Potential Protective Mechanism of Fenofibrate against High Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice.
    Jiang S; Uddin MJ; Yu X; Piao L; Dorotea D; Oh GT; Ha H
    Diabetes Metab J; 2022 Nov; 46(6):829-842. PubMed ID: 35746892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulation of hepatic CLOCK by PPARα is involved in inhibition of NAFLD.
    Luo J; Yan Z; Dai M; Xu L; Zhang H; Xi Y; Yang J; Liu A
    J Mol Med (Berl); 2023 Feb; 101(1-2):139-149. PubMed ID: 36527474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-alpha agonist treatment is accompanied by paradoxical increase of circulating resistin levels.
    Haluzik MM; Lacinova Z; Dolinkova M; Haluzikova D; Housa D; Horinek A; Vernerova Z; Kumstyrova T; Haluzik M
    Endocrinology; 2006 Sep; 147(9):4517-24. PubMed ID: 16740970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dietary isoflavone supplementation modulates lipid metabolism via PPARalpha-dependent and -independent mechanisms.
    Mezei O; Li Y; Mullen E; Ross-Viola JS; Shay NF
    Physiol Genomics; 2006 Jun; 26(1):8-14. PubMed ID: 16507786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fenofibrate A peroxisome proliferator activated receptor-α agonist treatment ameliorates Concanavalin A-induced hepatitis in rats.
    Mohamed DI; Elmelegy AA; El-Aziz LF; Abdel Kawy HS; El-Samad AA; El-Kharashi OA
    Eur J Pharmacol; 2013 Dec; 721(1-3):35-42. PubMed ID: 24140572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages
    Lefere S; Puengel T; Hundertmark J; Penners C; Frank AK; Guillot A; de Muynck K; Heymann F; Adarbes V; Defrêne E; Estivalet C; Geerts A; Devisscher L; Wettstein G; Tacke F
    J Hepatol; 2020 Oct; 73(4):757-770. PubMed ID: 32360434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fenofibrate, a peroxisome proliferator-activated receptor α ligand, prevents abnormal liver function induced by a fasting-refeeding process.
    Lee JN; Dutta RK; Kim SG; Lim JY; Kim SJ; Choe SK; Yoo KW; Song SR; Park DS; So HS; Park R
    Biochem Biophys Res Commun; 2013 Dec; 442(1-2):22-7. PubMed ID: 24211584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PPAR
    Mandala A; Chen WJ; Armstrong A; Malhotra MR; Chavalmane S; McCommis KS; Chen A; Carpenter D; Biswas P; Gnana-Prakasam JP
    Am J Physiol Gastrointest Liver Physiol; 2021 Sep; 321(4):G262-G269. PubMed ID: 34287090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective peroxisome proliferator-activated receptor-α modulator K-877 efficiently activates the peroxisome proliferator-activated receptor-α pathway and improves lipid metabolism in mice.
    Takei K; Han SI; Murayama Y; Satoh A; Oikawa F; Ohno H; Osaki Y; Matsuzaka T; Sekiya M; Iwasaki H; Yatoh S; Yahagi N; Suzuki H; Yamada N; Nakagawa Y; Shimano H
    J Diabetes Investig; 2017 Jul; 8(4):446-452. PubMed ID: 28084058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential gene expression in mouse primary hepatocytes exposed to the peroxisome proliferator-activated receptor alpha agonists.
    Guo L; Fang H; Collins J; Fan XH; Dial S; Wong A; Mehta K; Blann E; Shi L; Tong W; Dragan YP
    BMC Bioinformatics; 2006 Sep; 7 Suppl 2(Suppl 2):S18. PubMed ID: 17118139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.
    Cong WN; Tao RY; Tian JY; Liu GT; Ye F
    Life Sci; 2008 May; 82(19-20):983-90. PubMed ID: 18417155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of oleoylethanolamide on diet-induced nonalcoholic fatty liver in rats.
    Li L; Li L; Chen L; Lin X; Xu Y; Ren J; Fu J; Qiu Y
    J Pharmacol Sci; 2015 Mar; 127(3):244-50. PubMed ID: 25837920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kaempferol regulates the lipid-profile in high-fat diet-fed rats through an increase in hepatic PPARα levels.
    Chang CJ; Tzeng TF; Liou SS; Chang YS; Liu IM
    Planta Med; 2011 Nov; 77(17):1876-82. PubMed ID: 21728151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of peroxisome proliferator-activated receptor-alpha (PPARα) activity on adverse effects associated with amiodarone exposure in mice.
    Ernst MC; Sinal CJ; Pollak PT
    Pharmacol Res; 2010 Nov; 62(5):408-15. PubMed ID: 20654716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.